HPV vaccine study finds near-zero cervical cancer death risk before 30

No women aged 20 to 24 in England died from cervical cancer between 2020 and 2024, the first time that had happened over a five-year period, according to research reported by the BBC and The Straits Times. Without vaccination, around 23 deaths would have been expected in that age group.

The study, published in The Lancet and funded by Cancer Research UK, examined nationwide mortality data after England introduced HPV vaccination for girls aged 12 to 13 in 2008. The Straits Times reported that it was the first study of its kind to show the vaccine reduced the risk of dying from cervical cancer before age 30 to almost zero.

Researchers estimate that the HPV vaccination programme has saved about 200 young women’s lives in England so far, according to the BBC and India Today. In addition to the complete absence of deaths among women aged 20 to 24 between 2020 and 2024, The Straits Times reported an 80% reduction in the same age group during 2015 to 2019.

HPV, or human papillomavirus, is spread through close skin-to-skin contact and is thought to cause 99% of cervical cancer cases, according to the BBC. Most infections clear without serious consequences, but some lead to abnormal cell changes that can become cancer years later.

The public-health chain is unusually clear in this case. Vaccinating children at age 12 or 13 reduces later HPV infection risk; lower infection risk reduces the chance of abnormal cervical changes; fewer dangerous cell changes mean fewer cancers and deaths years later. The mortality data are now beginning to show that long delay between prevention and lives saved.

Cervical cancer has not disappeared. The BBC reported that it remains the 14th most common cancer among females in the UK, with 3,300 people diagnosed each year. Screening still matters, and the benefits of vaccination will expand only as vaccinated cohorts grow older and remain connected to cancer-prevention services.

The findings also come with a warning about coverage. Cancer Research UK described the result as an “incredible milestone,” the BBC reported, but warned that vaccination rates in England were below recommended levels. The Independent excerpt said experts were concerned about falling vaccination rates, with 71.7% of Year 8 girls and 67% of Year 8 boys vaccinated.

England’s programme was first rolled out for girls in 2008 and extended to boys in 2019, according to The Straits Times. India Today reported that coverage reached about 90% before the Covid-19 pandemic, and that a catch-up campaign also offered the vaccine to older teenage girls.

What remains uncertain is how quickly other countries can reproduce the same outcome. The evidence comes from England’s national vaccination and mortality data, with a school-based programme, screening infrastructure and long follow-up. Countries with lower uptake, weaker screening or disrupted health systems may not see the same speed of benefit.

The larger implication is practical: cervical cancer prevention now has mortality evidence, not only infection or precancer evidence, in young women vaccinated as children. A single adolescent public-health intervention is already visible years later in death records, turning vaccination coverage into a long-term cancer-prevention and health-equity measure.